First Dual GLP-1/GIP Receptor Agonist Shows Potential in Type 1 Diabetes Blood Sugar Management

Researchers have developed the first dual GLP-1/GIP receptor agonist specifically for the treatment of Type 1 diabetes, showing promising results in the control of blood glucose levels. The development targets a critical gap in Type 1 diabetes management, where patients rely entirely on exogenous insulin to regulate blood sugar.

The findings were highlighted in a report distributed via PR Newswire on June 5, 2026 and are associated with discussions surrounding the American Diabetes Association. The therapy utilizes a dual-agonist approach, targeting both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Unlike Type 2 diabetes, where the body becomes resistant to insulin or fails to produce enough of it, Type 1 diabetes is an autoimmune condition that destroys insulin-producing beta cells in the pancreas. While GLP-1 and GIP receptor agonists have been widely used to treat Type 2 diabetes and obesity, their application in Type 1 diabetes is a more recent area of clinical exploration.

The dual agonist mechanism is designed to improve glycemic stability by modulating the body’s response to glucose. GLP-1 agonists typically work by slowing gastric emptying and suppressing the secretion of glucagon, a hormone that raises blood glucose levels. The addition of GIP receptor agonism is intended to enhance these effects and potentially improve the metabolic profile of patients.

According to the reported findings, the dual agonist demonstrated promising benefits in blood glucose control. In the context of Type 1 diabetes, improved glucose control often manifests as a reduction in glycemic variability and an increase in the percentage of time patients spend within their target glucose range.

Medical professionals have noted that adjunct therapies for Type 1 diabetes are particularly valuable for managing the side effects of intensive insulin therapy. High doses of insulin can lead to weight gain and an increased risk of hypoglycemia, or dangerously low blood sugar. Therapies that can stabilize glucose levels while potentially reducing the total daily insulin requirement are a primary goal of current pharmaceutical research.

The integration of GIP agonism alongside GLP-1 is believed to provide a more synergistic effect than using a single-receptor agonist. This combination may help in reducing the overall glucose fluctuations that characterize the daily experience of those living with Type 1 diabetes.

Despite the promising initial results, the long-term safety and efficacy of dual GLP-1/GIP receptor agonists in Type 1 diabetes populations require further validation through extensive clinical trials. Researchers must continue to monitor for potential adverse effects, particularly the risk of severe hypoglycemia when these agents are combined with basal and bolus insulin regimens.

The development of this agonist represents a shift toward more personalized and multi-hormonal approaches to treating autoimmune diabetes. Future research will likely focus on determining the optimal dosage and identifying which patient subgroups benefit most from this dual-action therapy.